A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Banoxantrone (Primary)
- Indications Lymphoid leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2007 Status changed from recruiting to in progress.
- 26 Aug 2005 New trial record.